Axiom hopes it 'solved 2 major potholes' for stem cell biotechs

Axiom Biosciences' umbilical cord-derived mesenchymal stem cell therapy achieved 0% mortality in nine newborns with severe brain injury (IVH and HIE) in Phase 1, with no treatment-related serious adverse events. The company claims to have solved manufacturing control and blood-brain barrier delivery challenges that have historically delayed MSC therapies, and plans Phase 2b expansion into adult ischemic stroke.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.